Immune responses to vaccine antigens enhanced through adjuvant use

+Practice

In print

VACCINES

Immune responses to vaccine antigens enhanced through adjuvant use

3 August 2022

Mary Nowlan

Wednesday 3 August 2022, 12:15 AM

The dose-sparing role of adjuvants is important for rapid accessibility to pandemic strain-specific vaccines [Image: Garrett Dipuma on Wikimedia Commons CC BY-SA 2.0]

Vaccine adjuvants, in many different guises, are commonly used in vaccines and can augment the quality of immune responses to vaccine antigens. This article looks at the advantages of adjuvants, their diversity and why they are often needed

Key points, Infants and older adults have poorer responses to vaccines than the general population. The addition of adjuvants enhances the immune response to va, Pract Green w Pale Yellow

Vaccines

References

Pulendran B S, Arunachalam P, O’Hagan DT. Emerging concepts in the science of vaccine adjuvants. Nat Rev Drug Discov 2021;20(6):454–75.
Di Pasquale A, Preiss S, Tavares Da Silva F, et al. Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccines (Basel) 2015;3(2):320–43.
Editorial. Nanomedicine and the COVID-19 vaccines. Nat Nanotechnol 2020;15(12):963.
O’Hagan, D. Vaccine adjuvants 1 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. 2015. https://hstalks-com.ezproxy.auckland.ac.nz/bs/3061/ (requires login)
De Donato S, Granoff D, Minutello M, et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999;17(23):3094–101.
Vesikari T, Knuf M, Wutzler P, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011;365(15):1406–16.
O'Hagan DT, Ott GS, Nest GV, et al. The history of MF59 adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines 2013;12(1):13–30.
Keitel W, Groth N, Lattanzi M, et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial. Vaccine 2010;28(3):840–48.
Didierlaurent AM, Laupèze B, Di Pasquale A, et al. Adjuvant system AS01: helping to overcome the challenges of modern vaccines. Expert Rev Vaccines 2017;16(1):55–63.
Novavax. Our recombinant, protein-based nanoparticle vaccine technology. 2022. https://www.novavax.com/our-unique-technology#recombinant-nanoparticle-vaccine-technology
Lövgren Bengtsson K, Morein B, Osterhaus ADME. ISCOM technology-based Matrix M adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines 2011;10(4):401–03.
Black S, Della Cioppa G, Malfroot A, et al. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine 2010;28(45):7331–36.

How to Treat

+How to treat

COPD: Prevent, treat and comfort

Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management

Wednesday 26 March 2025, 12:50 AM